| HOME >> BIOLOGY >> TECHNOLOGY |
these rights, the fair values of the assets and liabilities of the
joint venture as of March 31, 2008 were not significant.
(2) As of March 31, 2008, Other assets includes $80,100K for the fair
value of the five million shares of Isis Pharmaceuticals, Inc. common
stock that we purchased in February 2008.
GENZYME CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP EARNINGS
For the Three Months Ended March 31, 2008
(Amounts in thousands, except per share data)
Dilution
Due to Premium on
Common Stock Strategic Equity
NON-GAAP Equivalents Investment
Income Statement
Classification:
Total revenues $1,100,061
Cost of products
and services sold $(265,799)
Selling, general and
administrative $(295,497)
Research and development $(180,312) $(69,900)
Amortization of
intangibles $-
Equity in income (loss)
of equity method
investments $188
Minority interest $463
Gains (losses) on
investments in equity
securities $775
Other $(160)
Investment income $14,870
Interest expense $(1,655)
Summary:
Income (loss) before
income taxes $372,934 $- $(69,900)
(Provision for) benefit
from income taxes $(112,039) $- $13,428
Net income (loss) $260,895
'/>"/>
| SOURCE Genzyme Corp. Copyright©2008 PR Newswire. All rights reserved |